Sanz-Cuesta BE, et al. - A systematic comparative meta-analysis was performed to evaluate hemorrhagic stroke (HS) rates across all completed statin and PCSK9I randomized clinical trials with treatment > 3 months, following PRISMA guidelines. Causal relation was probed by assessing for dose-response relationships by medication (low vs high medication dose/potency) and by presence and type of preceding brain vascular events at inception (none versus ischemic stroke/transient ischemic attack versus HS) in addition to HS rates across all trials. Researchers conducted a systematic review to distinguish 36 statin randomized clinical trials (204,918 patients) and 5 PCSK9I randomized clinical trials (76,140 patients). The risk of HS was increased by statin in a medication dose- and type of index brain vascular injury-dependent manner; PCSK9Is do not increase HS risk. It has been considered that PCSK9Is may be a preferred lipid-lowering medication class in patients with elevated HS risk, including patients with prior HS.